Switch from NNRTI-Based Regimen to EVG-COBI-TDF-FTC

Study 121 (STRATEGY-NNRTI)
Switch from NNRTI-Based Regimen to EVG-COBI-TDF-FTC STRATEGY-NNRTI: Design

Study Design: STRATEGY-NNRTI

- **Background:** Open-label, randomized, Phase 3b trial comparing switch to elvitegravir-cobicistat-tenofovir DF-emtricitabine versus continuation of baseline regimen of NNRTI + TDF-FTC

- **Inclusion Criteria (n = 439)**
  - HIV RNA <50 copies/mL on ART for ≥6 months
  - Baseline regimen of NNRTI + TDF-FTC
  - No prior virologic failure
  - No resistance to TDF or FTC or
  - CrCl ≥70 mL/min

- **Treatment Arms**
  - EVG-COBI-FTC-TDF (Switch group)
  - Remain on NNRTI + FTC-TDF (No switch group)

*NOTE:* 2 participants from switch group and 4 participants from no-switch group were excluded from the study after screening (2 protocol violation, 1 non-adherence, 3 withdrew consent)

Switch from NNRTI-Based Regimen to EVG-COBI-TDF-FTC STRATEGY-NNRTI: Result

Week 48: Virologic Response (Modified Intent-to-Treat Analysis)

Switch from NNRTI-Based Regimen to EVG-COBI-TDF-FTC STRATEGY-NNRTI: Subgroup Analysis Result

Week 48 Virologic Response, by Baseline NNRTI Regimen

![Bar chart showing virologic response at Week 48 by baseline NNRTI regimen.]

- **EVG-COBI-TDF-FTC (Switch):**
  - Efavirenz: 214/231 (93%)
  - Nevirapine or Rilpivirine: 57/59 (97%)

- **NNRTI + TDF-FTC (No switch):**
  - Efavirenz: 91/106 (86%)
  - Nevirapine or Rilpivirine: 35/37 (95%)

Switch from NNRTI-Based Regimen to EVG-COBI-TDF-FTC

STRATEGY-NNRTI: Subgroup Analysis Result

Week 48 Virologic Response, by Baseline NNRTI Regimen

Interpretation: “Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir seems to be efficacious and well tolerated in virologically suppressed adults with HIV and might be a suitable alternative for patients on an NNRTI with emtricitabine and tenofovir regimen considering a regimen modification or simplification.”

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*